{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:52:43Z","timestamp":1789239163805,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T00:00:00Z","timestamp":1351209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Aya Miyagawa-Hayashino and Atushi Yoshizawa"},{"name":"Next Generation World-Leading Researchers"},{"name":"Council for Science and Technology Policy"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The role of donor-specific anti-human leukocyte antigen antibodies (DSAs) that develop late after living donor liver transplantation is unknown. Seventy-nine pediatric recipients who had good graft function and underwent protocol liver biopsy more than 5 years after transplantation (median = 11 years, range = 5-20 years) were reviewed. DSAs were determined with the Luminex single-antigen bead assay at the time of the last biopsy, and complement component 4d (C4d) immunostaining was assessed at the times of the last biopsy and the previous biopsy. The donor specificity of antibodies could be identified in 67 patients: DSAs were detected in 32 patients (48%), and they were usually against human leukocyte antigen class II (30 cases) but were rarely against class I (2 cases). These patients had a higher frequency of bridging fibrosis or cirrhosis (28\/32 or 88%) than DSA-negative patients (6\/35 or 17%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Fibrosis was likely to be centrilobular-based. DSA-positive patients, in comparison with DSA-negative patients, had higher frequencies of diffuse\/focal endothelial C4d staining (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and mild\/indeterminate acute rejection [15\/32 (47%) versus 5\/35 (14%),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004]. Four DSA-negative patients were off immunosuppression, whereas no patients in the DSA-positive group were (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.048). In conclusion, the high prevalence of graft fibrosis and anti\u2013class II DSAs in late protocol biopsy samples suggests that humoral alloreactivity may contribute to the process of unexplained graft fibrosis late after liver transplantation. Liver Transpl 18:1333\u20131342, 2012. \u00a9 2012 AASLD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lt.23534","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T06:54:58Z","timestamp":1344581698000},"page":"1333-1342","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":177,"title":["Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts"],"prefix":"10.1097","volume":"18","author":[{"given":"Aya","family":"Miyagawa-Hayashino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Yurugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Uemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"676684","DOI":"10.1038\/modpathol.3800784","article-title":"Significance of C4d staining in ABOidenticalcompatible liver transplantation.","volume":"20","author":"Sakashita","year":"2007","journal-title":"Mod Pathol"},{"key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"506509","DOI":"10.1097\/01.tp.0000251361.12249.a1","article-title":"Antidonor antibody in patients receiving ABOidentical and HLAmismatched living donor liver transplants: effect on survival.","volume":"83","author":"Ashihara","year":"2007","journal-title":"Transplantation"},{"key":"R3-11-20250124","first-page":"554562","article-title":"Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility.","volume":"14","author":"CastilloRama","year":"2008","journal-title":"Liver Transpl"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"308313","DOI":"10.1002\/lt.21981","article-title":"Human leukocyte antigen crossmatch testing is important for liver retransplantation.","volume":"16","author":"Goh","year":"2010","journal-title":"Liver Transpl"},{"key":"R5-11-20250124","doi-asserted-by":"crossref","first-page":"171182","DOI":"10.1111\/j.1600-6143.2011.03786.x","article-title":"Reexamination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?","volume":"12","author":"Lunz","year":"2012","journal-title":"Am J Transplant"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"15051513","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Antihuman leukocyte antigen and donorspecific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"25322541","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donorspecific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure.","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"R8-11-20250124","doi-asserted-by":"crossref","first-page":"568575","DOI":"10.1097\/00007890-199902270-00014","article-title":"Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection.","volume":"67","author":"Kasahara","year":"1999","journal-title":"Transplantation"},{"key":"R9-11-20250124","first-page":"858859","article-title":"Prevalence of antiHLA antibodies after liver transplantation.","volume":"23","author":"Fontana","year":"2010","journal-title":"Transpl Int"},{"key":"R10-11-20250124","doi-asserted-by":"crossref","first-page":"500510","DOI":"10.1111\/j.1600-6143.2010.03414.x","article-title":"The significance of donorspecific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.","volume":"11","author":"Musat","year":"2011","journal-title":"Am J Transplant"},{"key":"R11-11-20250124","first-page":"18681876","article-title":"High mean fluorescence intensity donorspecific antiHLA antibodies associated with chronic rejection postliver transplant.","volume":"11","author":"OLeary","year":"2011","journal-title":"Am J Transplant"},{"key":"R12-11-20250124","doi-asserted-by":"crossref","first-page":"518526","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"15821587","DOI":"10.1002\/lt.21549","article-title":"Graft histology characteristics in longterm survivors of pediatric liver transplantation.","volume":"14","author":"Ekong","year":"2008","journal-title":"Liver Transpl"},{"key":"R14-11-20250124","doi-asserted-by":"crossref","first-page":"880886","DOI":"10.1002\/hep.22686","article-title":"Graft fibrosis after pediatric liver transplantation: ten years of followup.","volume":"49","author":"Scheenstra","year":"2009","journal-title":"Hepatology"},{"key":"R15-11-20250124","doi-asserted-by":"crossref","first-page":"828836","DOI":"10.1097\/00007890-200209270-00017","article-title":"Centrilobular fibrosis in longterm followup of pediatric liver transplant recipients.","volume":"74","author":"Martin","year":"2002","journal-title":"Transplantation"},{"key":"R16-11-20250124","doi-asserted-by":"crossref","first-page":"152160","DOI":"10.1002\/lt.20358","article-title":"Longterm outcome of pediatric liver transplantation for biliary atresia: a 10year followup in a single center.","volume":"11","author":"Fouquet","year":"2005","journal-title":"Liver Transpl"},{"key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"283293","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants.","volume":"307","author":"Feng","year":"2012","journal-title":"JAMA"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"30223029","DOI":"10.1111\/j.1600-6143.2006.01554.x","article-title":"Isolated donor specific alloantibodymediated rejection after ABO compatible liver transplantation.","volume":"6","author":"Watson","year":"2006","journal-title":"Am J Transplant"},{"key":"R19-11-20250124","doi-asserted-by":"crossref","first-page":"357368","DOI":"10.1002\/lt.22233","article-title":"Liver allograft antibodymediated rejection with demonstration of sinusoidal C4d staining and circulating donorspecific antibodies.","volume":"17","author":"Kozlowski","year":"2011","journal-title":"Liver Transpl"},{"key":"R20-11-20250124","first-page":"6269","article-title":"Significance of complement split product C4d in ABOcompatible liver allograft: diagnosing utility in acute antibody mediated rejection.","volume":"26","author":"Ali","year":"2011","journal-title":"Transpl Immunol"},{"key":"R22-11-20250124","doi-asserted-by":"crossref","first-page":"598607","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases.","volume":"47","author":"Goodman","year":"2007","journal-title":"J Hepatol"},{"key":"R24-11-20250124","first-page":"15991608","article-title":"Clinicopathological analysis of liver allograft biopsies with late centrilobular necrosis: a comparative study in 54 patients.","volume":"69","author":"Nakazawa","year":"2000","journal-title":"Transplantation"},{"key":"R25-11-20250124","doi-asserted-by":"crossref","first-page":"11411147","DOI":"10.1053\/jhep.2001.23938","article-title":"Central venulitis in pediatric liver allografts.","volume":"33","author":"Krasinskas","year":"2001","journal-title":"Hepatology"},{"key":"R26-11-20250124","doi-asserted-by":"crossref","first-page":"270276","DOI":"10.1053\/hupa.2002.32225","article-title":"Centrilobular histopathologic changes in liver transplant biopsies.","volume":"33","author":"Khettry","year":"2002","journal-title":"Hum Pathol"},{"key":"R27-11-20250124","doi-asserted-by":"crossref","first-page":"10331041","DOI":"10.1111\/j.1600-6143.2004.00500.x","article-title":"National conference to assess antibodymediated rejection in solid organ transplantation.","volume":"4","author":"Takemoto","year":"2004","journal-title":"Am J Transplant"},{"key":"R28-11-20250124","first-page":"807817","article-title":"Antibodymediated organallograft rejection.","volume":"5","author":"Colvin","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"R29-11-20250124","doi-asserted-by":"crossref","first-page":"747750","DOI":"10.1002\/lt.22323","article-title":"Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls.","volume":"17","author":"Bellamy","year":"2011","journal-title":"Liver Transpl"},{"key":"R30-11-20250124","doi-asserted-by":"crossref","first-page":"739749","DOI":"10.1111\/j.1365-2559.2007.02677.x","article-title":"C4d immunopositivity is uncommon in ABOcompatible liver allografts, but correlates partially with lymphocytotoxic antibody status.","volume":"50","author":"Bellamy","year":"2007","journal-title":"Histopathology"},{"key":"R31-11-20250124","doi-asserted-by":"crossref","first-page":"23712380","DOI":"10.1097\/01.ASN.0000025780.03790.0F","article-title":"Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection.","volume":"13","author":"Regele","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R32-11-20250124","doi-asserted-by":"crossref","first-page":"274276","DOI":"10.1016\/j.humimm.2009.12.002","article-title":"Liver transplant recipients weaned off immunosuppression lack circulating donorspecific antibodies.","volume":"71","author":"Girnita","year":"2010","journal-title":"Hum Immunol"},{"key":"R33-11-20250124","doi-asserted-by":"crossref","first-page":"25202531","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibodymediated microcirculation injury is the major cause of late kidney transplant failure.","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant"},{"key":"R35-11-20250124","doi-asserted-by":"crossref","first-page":"655659","DOI":"10.1016\/j.humimm.2009.04.019","article-title":"Monitoring and treating posttransplant human leukocyte antigen antibodies.","volume":"70","author":"Everly","year":"2009","journal-title":"Hum Immunol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23534","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201211000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T12:21:32Z","timestamp":1737721292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201211000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23534","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}